Identification | Back Directory | [Name]
ethyl N-(5-ethyl-6-oxobenzo[b][1,4]benzoxazepin-8-yl)carbamate | [CAS]
922029-50-3 | [Synonyms]
ethyl N-(5-ethyl-6-oxobenzo[b][1,4]benzoxazepin-8-yl)carbamate | [Molecular Formula]
C18H18N2O4 | [MOL File]
922029-50-3.mol | [Molecular Weight]
326.347 |
Hazard Information | Back Directory | [Description]
Angiogenesis inhibitor BT2 is a novel inhibitor of angiogenesis and vascular permeability, inhibiting ERK phosphorylation and the expression of FosB/ΔFosB, VCAM-1, and many genes involved in proliferation, migration, angiogenesis, and inflammation, interacting with MEK1, suppressing retinal CD31, pERK, VCAM-1, and VEGF-A165 expression. | [Uses]
Angiogenesis inhibitor 7 (compound BT2) ia a potent inhibitor of angiogenesis. Angiogenesis inhibitor 7 inhibits ERK phosphorylation, FosB/ΔFosB and VCAM-1 expression[1]. | [References]
[1] NewSouth Innovations Pty Limited. Treatment methods comprising administering inhibitors of FosB/ΔFosB expression and/or VCAM-1 expression and/or ERK1/2 phosphorylation. World Intellectual Property Organization, WO2021184059 A1 2021-09-23 |
|
|